Top Medical News
Fewer hospitalizations with omicron vs delta suggest reduced severity of omicron variant
Roshini Claire Anthony, Yesterday

Infection with the omicron variant of SARS-CoV-2 was less likely to result in hospitalization than infection with the delta variant, according to an observational study from Denmark presented at ECCMID 2022 and published in The Lancet.

Obesity, sleep apnoea do not contribute to increased sarcoidosis risk
Increased body mass index does not seem to raise the risk of developing sarcoidosis, according to a study. Furthermore, the presence of obstructive sleep apnoea even confers protection.
Male sex, obesity among risk factors for severe COVID-19 in children
Roshini Claire Anthony, 4 days ago

A large study by the US National COVID Cohort Collaborative (N3C) has identified factors associated with the risk of severe disease among children with SARS-CoV-2 infection as well as factors tied to an increased risk of multisystem inflammatory syndrome in children (MIS-C) as compared to acute COVID-19.

Nasal microbiome predicts bronchopulmonary dysplasia in preterm infants
5 days ago
In infants born preterm, the nasal microbiome seems to correlate with the incidence and severity of bronchopulmonary dysplasia, reports a recent study.
4th shot of COVID vax: Where from here?
Pearl Toh, 5 days ago
Having a fourth dose of COVID-19 vaccine (ie, second booster dose) substantially protects against severe illness in face of the Omicron variant, compared with only three doses of vaccine that were given more than 4 months earlier, according to data from the Israeli Ministry of Health database.
No apparent link between COVID-19 vax and cerebrovascular outcomes
Roshini Claire Anthony, 13 May 2022

Several studies presented at AAN 2022 have revealed a lack of association between COVID-19 vaccination and negative cerebrovascular outcomes.

Special Reports
Product Highlight - Bilaxten ODT
16 Mar 2022
Bilastine 10 mg orodispersible tablet
Kids hard-hit by Delta; which ART performs best?
Elvira Manzano, 24 Oct 2021
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
Rapid antigen test: Don’t let perfect be the enemy of good
Pearl Toh, 23 Oct 2021
While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.
ID NOW rapid molecular assay an effective COVID-19 test for kids
Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Antigen rapid tests: The new COVID-19 strategy moving forward?
Roshini Claire Anthony, 31 Jul 2021

Same-day pre-event screening for SARS-CoV-2 using antigen-detecting rapid diagnostic tests (Ag-RDT) may enable the resumption of large-scale indoor events which were halted or had their attendance capacity reduced during the COVID-19 pandemic, according to a study from Spain presented at ECCMID 2021.

Combined Ag/Ab rapid testing boosts case-finding in COVID-19
Elvira Manzano, 29 Jul 2021
A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.
Conference Reports
Sotorasib continues to impress at 2 years in KRAS G12C–mutant NSCLC
Elvira Manzano, 13 May 2022
Long-term findings from the pooled phase I/II CodeBreak 100 trial support the efficacy of sotorasib in certain patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC).
Adding canakinumab to SoC confers no survival benefit in advanced NSCLC
Roshini Claire Anthony, 10 May 2022

The addition of the monoclonal anti-interleukin-1β antibody canakinumab to the standard of care (SoC) regimen of platinum doublet chemotherapy and pembrolizumab in the first-line setting did not improve progression-free survival (PFS) or overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC), results of the phase III CANOPY-1 trial showed.

First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC
Roshini Claire Anthony, 06 May 2022

Treatment comprising camrelizumab, carboplatin, and paclitaxel in the first-line setting improved overall survival (OS) in patients with advanced squamous non-small-cell lung cancer (NSCLC), according to updated results of the phase III CameL-sq trial from China.

Adding durvalumab upfront to chemo ups long-term survival in SCLC
Pearl Toh, 05 May 2022
Patients were threefold more likely to survive long term (beyond 3 years) when durvalumab was added to first-line chemotherapy, with or without tremelimumab, compared with those on chemotherapy alone, according to a post hoc analysis of long-term survivors (LTS) with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study.
Furmonertinib emerges as potential first-line option for EGFRm NSCLC
Roshini Claire Anthony, 22 Apr 2022

Treatment-naïve patients with locally advanced or metastatic EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) experience improved progression-free survival (PFS) when treated with furmonertinib compared with gefitinib, according to results of the phase III FURLONG study.

SPOTLIGHT: Durvalumab shines in real-world trial on NSCLC
Audrey Abella, 21 Apr 2022
Findings from the SPOTLIGHT trial have shown the efficacy of administering durvalumab after chemoradiotherapy (CRT) in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
Anaphylaxis after COVID mRNA vaccination relatively rare
Roshini Claire Anthony, 06 Apr 2022

Anaphylactic reactions warranting treatment after receipt of COVID-19 mRNA vaccinations appear to be relatively rare, according to a US study presented at AAAAI 2022.